Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Anneke D. van Dijk, Peter P. Ruvolo, Fieke W. Hoff, Yihua Qiu, Alan S. Gamis, Richard Aplenc, Anders E. Kolb, Todd A. Alonzo, Robert B. Gerbing, Eveline S. de Bont, Sophia W. M. Bruggeman, Terzah M. Horton, Steven M. Kornblau


Originele taal-2English
Aantal pagina's4
StatusPublished - 13-nov.-2019
Evenement61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - Orlando
Duur: 7-dec.-201910-dec.-2019

Citeer dit